RAS突变在恶性肿瘤的研究进展
周乐芬 （ 庆元县人民医院 ）
陈小明 （ 庆元县人民医院 ）
https://doi.org/10.37155/2661-4766-0504-46Abstract
恶性肿瘤是指机体在各种致癌因素作用下，组织细胞在基因水平上失去对其生长的正常调控，导致细胞 克隆性异常增生而形成的新生物。肿瘤本质是一种基因病，目前已知人类恶性肿瘤中高达30%的恶性肿瘤存在RAS基 因激活突变， KRAS突变是最为常见的突变，然而KRAS突变长久以来被认为是“不可成药”靶点。 KRAS G12C基因 突变的抑制剂AMG 510（ Sotorasib）打破了KRAS靶点无药可用的局面，而Adagrasib也展现出相似的全身疗效和抗肿 瘤活性。本文主要根据RAS基因突变特性在各个癌种的进展情况及现有的靶向治疗进行综述。
Keywords
恶性肿瘤； RAS突变； KRASG12CFull Text
PDFReferences
[1]Murugan AK, Grieco M, Tsuchida N. RAS
mutations in human cancers: Roles in precision medicine.
Semin Cancer Biol. 2019 Dec;59:23-35. doi: 10.1016/
j.semcancer.2019.06.007. Epub 2019 Jun 27. PMID: 31255772.
[2]Kwong LN, Costello JC, Liu H, Jiang S, Helms TL,
Langsdorf AE, Jakubosky D, Genovese G, Muller FL, Jeong
JH, Bender RP, Chu GC, Flaherty KT, Wargo JA, Collins JJ,
Chin L. Oncogenic NRAS signaling differentially regulates
survival and proliferation in melanoma. Nat Med. 2012
Oct;18(10):1503-10. doi: 10.1038/nm.2941. Epub 2012 Sep
16. Erratum in: Nat Med.
[3]Adderley H, Blackhall FH, Lindsay CR. KRASmutant non-small cell lung cancer: Converging small
molecules and immune checkpoint inhibition. EBioMedicine.
2019 Mar;41:711-716. doi: 10.1016/j.ebiom.2019.02.049.
Epub 2019 Mar 7. PMID: 30852159; PMCID: PMC6444074.
[4]Moore AR, Rosenberg SC, McCormick F, Malek S.RAS-targeted therapies. Nat Rev Drug Discov. 2021 May
14. doi: 10.1038/s41573-021-00220-6. Epub ahead of print.
PMID: 33990767.
[5]Waters AM, Der CJ. KRAS: The Critical Driver
and Therapeutic Target for Pancreatic Cancer. Cold
Spring Harb Perspect Med. 2018 Sep 4;8(9):a031435. doi:
10.1101/cshperspect.a031435. PMID: 29229669; PMCID:
PMC5995645.
[6]Hainsworth JD, Cebotaru CL, Kanarev V, Ciuleanu
TE, Damyanov D, Stella P, Ganchev H, Pover G, Morris C,
Tzekova V. A phase II, open-label, randomized study to assess
the efficacy and safety of AZD6244 (ARRY-142886) versus
pemetrexed in patients with non-small cell lung cancer who
have failed one or two prior chemotherapeutic regimens.
J Thorac Oncol. 2010 Oct;5(10):1630-6. doi: 10.1097/
JTO.0b013e3181e8b3a3. PMID: 20802351.
mutations in human cancers: Roles in precision medicine.
Semin Cancer Biol. 2019 Dec;59:23-35. doi: 10.1016/
j.semcancer.2019.06.007. Epub 2019 Jun 27. PMID: 31255772.
[2]Kwong LN, Costello JC, Liu H, Jiang S, Helms TL,
Langsdorf AE, Jakubosky D, Genovese G, Muller FL, Jeong
JH, Bender RP, Chu GC, Flaherty KT, Wargo JA, Collins JJ,
Chin L. Oncogenic NRAS signaling differentially regulates
survival and proliferation in melanoma. Nat Med. 2012
Oct;18(10):1503-10. doi: 10.1038/nm.2941. Epub 2012 Sep
16. Erratum in: Nat Med.
[3]Adderley H, Blackhall FH, Lindsay CR. KRASmutant non-small cell lung cancer: Converging small
molecules and immune checkpoint inhibition. EBioMedicine.
2019 Mar;41:711-716. doi: 10.1016/j.ebiom.2019.02.049.
Epub 2019 Mar 7. PMID: 30852159; PMCID: PMC6444074.
[4]Moore AR, Rosenberg SC, McCormick F, Malek S.RAS-targeted therapies. Nat Rev Drug Discov. 2021 May
14. doi: 10.1038/s41573-021-00220-6. Epub ahead of print.
PMID: 33990767.
[5]Waters AM, Der CJ. KRAS: The Critical Driver
and Therapeutic Target for Pancreatic Cancer. Cold
Spring Harb Perspect Med. 2018 Sep 4;8(9):a031435. doi:
10.1101/cshperspect.a031435. PMID: 29229669; PMCID:
PMC5995645.
[6]Hainsworth JD, Cebotaru CL, Kanarev V, Ciuleanu
TE, Damyanov D, Stella P, Ganchev H, Pover G, Morris C,
Tzekova V. A phase II, open-label, randomized study to assess
the efficacy and safety of AZD6244 (ARRY-142886) versus
pemetrexed in patients with non-small cell lung cancer who
have failed one or two prior chemotherapeutic regimens.
J Thorac Oncol. 2010 Oct;5(10):1630-6. doi: 10.1097/
JTO.0b013e3181e8b3a3. PMID: 20802351.
Copyright © 2023 周乐芬,陈小明
Publishing time:2023-08-31
This work is licensed under a Creative Commons Attribution 4.0 International License
Email
Location